Name
Session 10: Day 2 Kickoff & First-Line RCC Debate: TKI vs. IO for Favorable Risk
Date & Time
Saturday, May 3, 2025, 9:15 AM - 10:30 AM
Speakers
Axel Bex, The Netherlands Cancer Institute, Amsterdam
Laurence Albiges, Gustave Roussy
Gabriel Malouf, Icans
Salvo La Rosa, Kidney Cancer Association
Lisa Pickering, Royal Marsden
Stéphane OUDARD, Georges Pompidou Hospital
Ignacio Duran, HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA
Laurence Albiges, Gustave Roussy
Gabriel Malouf, Icans
Salvo La Rosa, Kidney Cancer Association
Lisa Pickering, Royal Marsden
Stéphane OUDARD, Georges Pompidou Hospital
Ignacio Duran, HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA
Description
Chairs: Gabriel Malouf, MD and Laurence Albiges, MD, PhD
Planning Committee Welcome to Day 2: Lisa Pickering, MD and Ignacio Duran, MD, PhD
Recognizing the Planning Committee's Contributions: Salvatore La Rosa, PhD
What is the Current Optimal Treatment for Favorable Risk Group mRCC?: Stéphane Oudard, MD
IO-IO or IO-TKI? Decoding Choices for Intermediate and Poor Prognosis: Laurence Albiges, MD, PhD
The Role of IO Post-Adjuvant Pembrolizumab: Fact or Fiction?: Ignacio Duran, MD, PhD
Local Therapy for Oligo-Progression: Surgery, Radiotherapy, or Both?: Axel Bex, MD, PhD
Moderated Q&A: Gabriel Malouf, MD and Laurence Albiges, MD, PhD
Location Name
Grote Zaal
Full Address
Beurs van Berlage
Damrak 243
Amsterdam-Centrum
Amsterdam NH 1012 ZJ
Netherlands
Damrak 243
Amsterdam-Centrum
Amsterdam NH 1012 ZJ
Netherlands